-
Published 3/7/2025
Sofoluwe A, Ferri G, Sloan JM, Caron J, Thomasson RR. Implementation of a Duffy antigen screening test order with interpretation guide to help optimize resource allocation at an urban safety-net hospital. Transfusion. 2025 Apr; 65(4):652-653. PMID: 40055154.
-
Published 12/10/2024
Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.
-
Published 11/26/2024
Sanchorawala V, Barroso B, Shelton A, Goetz E, Mendelson L, Joshi T, Burke N, Sloan JM, Staron A. Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment. Blood Adv. 2024 Nov 26; 8(22):5826-5828. PMID: 39293090.
-
Published 11/22/2024
Reifler KA, Francoeur Smith T, Bodanapu G, Fagan M, Bourque DL, Sloan JM. Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston. Leuk Res Rep. 2024; 22:100489. PMID: 39659827.
-
Published 9/3/2024
Hibbs SP, Aiken L, Vora K, Mowete C, Merz LE, Apea V, Sloan JM, Lathan CS, Abel GA, Hantel A. Cancer Trial Eligibility and Therapy Modifications for Individuals With Duffy Null-Associated Neutrophil Count. JAMA Netw Open. 2024 Sep 03; 7(9):e2432475. PMID: 39259539.